company background image
OPT logo

Opthea ASX:OPT Stock Report

Last Price

AU$0.48

Market Cap

AU$321.5m

7D

0%

1Y

-13.4%

Updated

13 Jun, 2024

Data

Company Financials +

OPT Stock Overview

A clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia.

OPT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Opthea Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Opthea
Historical stock prices
Current Share PriceAU$0.48
52 Week HighAU$0.81
52 Week LowAU$0.31
Beta0.70
1 Month Change-25.38%
3 Month Change-21.14%
1 Year Change-13.39%
3 Year Change-70.87%
5 Year Change-20.49%
Change since IPO708.33%

Recent News & Updates

Recent updates

Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

Jul 21
Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?

Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

Mar 24
Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation

We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

Dec 09
We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely

This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Oct 12
This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate

Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

Aug 24
Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation

We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth

Mar 01
We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth

What Type Of Shareholders Make Up Opthea Limited's (ASX:OPT) Share Registry?

Dec 13
What Type Of Shareholders Make Up Opthea Limited's (ASX:OPT) Share Registry?

Shareholder Returns

OPTAU BiotechsAU Market
7D0%-1.5%-0.7%
1Y-13.4%-0.5%8.2%

Return vs Industry: OPT underperformed the Australian Biotechs industry which returned -0.5% over the past year.

Return vs Market: OPT underperformed the Australian Market which returned 8.2% over the past year.

Price Volatility

Is OPT's price volatile compared to industry and market?
OPT volatility
OPT Average Weekly Movement7.8%
Biotechs Industry Average Movement11.4%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market3.2%

Stable Share Price: OPT's share price has been volatile over the past 3 months.

Volatility Over Time: OPT's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198424Fred Guerardopthea.com

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company’s development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3”, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema.

Opthea Limited Fundamentals Summary

How do Opthea's earnings and revenue compare to its market cap?
OPT fundamental statistics
Market capAU$321.46m
Earnings (TTM)-AU$242.69m
Revenue (TTM)AU$586.33k

548.3x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OPT income statement (TTM)
RevenueUS$390.44k
Cost of RevenueUS$233.89k
Gross ProfitUS$156.55k
Other ExpensesUS$161.76m
Earnings-US$161.61m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.24
Gross Margin40.10%
Net Profit Margin-41,391.02%
Debt/Equity Ratio-385.3%

How did OPT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.